All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention Ibogaine, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Psyence Labs Ltd., all published on February 21, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Psyence Labs Ltd.
All 1 tracked stories fall under one category: funding. Of the tracked stories, 1 of 1 also mention Ibogaine, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Healthcare story that mention Psyence Labs Ltd., all published on February 21, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Psyence Labs Ltd.. Shared-story counts are live from our verified record — not editorial picks.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds.